Inflammatory Genes and Long COVID Persistence | Decoding Inflammation

By Decoding Inflammation · 2026-06-30 · 9 min

Two people catch the same virus. One recovers in two weeks. The other is still sick six months later. Fatigue, brain fog, breathlessness, and pain persist without a clear explanation. The virus is gone. The infection is over. The body keeps responding as though it is not.

This is Long COVID, the clinical name for post-acute sequelae of SARS-CoV-2 infection, a condition in which symptoms continue or emerge weeks and months after the acute phase of COVID-19 has resolved. Research published in Nature Immunology in December 2025 by Aid, Boero-Teyssier, McMahan, and colleagues at Beth Israel Deaconess Medical Center confirmed that Long COVID involves persistent activation of pro-inflammatory signaling pathways for more than 180 days after initial infection. The immune system does not return to its pre-infection baseline. It remains engaged, and the biological cost of that engagement accumulates across organs and tissues over time.

The question that genomic science now asks is why this happens in some people and not others. The answer involves the genes that regulate the volume, duration, and resolution of the inflammatory response.

THE CYTOKINE SIGNALING SYSTEM

When the immune system detects an infection, it releases cytokines, small protein molecules that carry chemical signals between immune cells. Cytokines coordinate the immune response. They recruit immune cells to the site of infection, raise the body's temperature, and amplify the attack. Interleukin-6, a cytokine commonly abbreviated as IL-6, and tumor necrosis factor alpha, a cytokine abbreviated as TNF-α, are two of the most studied drivers of this inflammatory signal in COVID-19.

The Beth Israel Deaconess research team found that the IL-6 signaling pathway remained upregulated in Long COVID patients across both their 2020-2021 and 2023-2024 study cohorts. T cell exhaustion, a state in which immune cells lose their functional capacity after prolonged activation, also characterized the Long COVID group. The immune system had been running its alert signal for so long that the cells executing the response had worn out.

Research published in Virology Journal in 2024 by Yip and colleagues documented that genetic variants, inherited differences in the DNA sequence of key inflammatory genes, in the IL-6, IL-8, and TNF-α genes alter the volume of cytokine output the immune system produces in response to viral stimulation. These variants sit in the promoter region, the section of DNA that controls how actively a gene gets read and translated into protein. A person who carries high-output promoter variants in the IL-6 gene produces more IL-6 when the immune system activates. A person who carries high-output variants in the TNF-α gene sustains a stronger tumor necrosis factor signal for longer. These genomic differences were present before the person ever encountered SARS-CoV-2. The virus did not create the elevated response. It activated a system the genome had already configured.

A meta-analysis on persistent inflammatory cytokine signatures in Long COVID confirmed that elevated IL-6 and TNF-α levels persist in post-acute COVID-19 patients well beyond the point of clinical recovery. The cytokine signal does not resolve with the infection. In people whose genomes carry high-output variants, that persistent signal runs at a higher amplitude.

THE LUNG GENE AND THE RECOVERY WINDOW

A genome-wide association study published in Nature Genetics in May 2025, analyzing data from 6,450 Long COVID cases and more than one million population controls across 24 contributing research groups, identified a genome-wide significant association between Long COVID and a genetic locus upstream of the FOXP4 gene on chromosome 6. FOXP4 is a transcription factor, a protein that binds to DNA and controls whether other genes get switched on or off. FOXP4 plays an established role in lung development and the maintenance of healthy pulmonary tissue.

The research team found that FOXP4 expression was elevated in blood samples from Long COVID patients compared with people who recovered from COVID-19 without persistent symptoms. This finding suggests that FOXP4 activity does not simply return to its pre-infection level after the virus clears. In people who carry the risk variant, the gene continues to express at a higher level, sustaining a biological state that the lungs and immune system interpret as ongoing stress.

This is a genomic vulnerability that operated before the person ever contracted COVID-19. The variant does not cause disease on its own. When SARS-CoV-2 activates the pathways that FOXP4 regulates, a person carrying the risk variant enters the recovery period with a gene already tuned toward sustained rather than resolved activity.

THE IMMUNE EXHAUSTION ENDPOINT

The Beth Israel Deaconess research identified T cell exhaustion as a consistent feature of Long COVID across both study cohorts. T cells are the immune cells responsible for targeting and clearing virus-infected cells. When T cells exhaust, they lose their ability to respond effectively. They continue to receive the inflammatory signal but lose the capacity to act on it. The result is a system that keeps generating the alarm and loses the ability to resolve the emergency.

Genetic variants that increase cytokine output contribute to the conditions that accelerate T cell exhaustion. A genome that drives higher IL-6 signaling sustains the inflammatory environment in which T cells exhaust more rapidly and more completely. The JAK-STAT pathway, a series of intracellular signaling proteins that carry the IL-6 signal from the cell surface into the nucleus, also showed persistent upregulation in Long COVID patients in the Beth Israel Deaconess data. The JAK-STAT proteins do not simply relay the IL-6 message. They amplify it. A genome configured to produce more IL-6 feeds a JAK-STAT pathway that amplifies that signal inside every cell it reaches.

WHY THIS MATTERS FOR UNDERSTANDING LONG COVID

Long COVID research has expanded rapidly since 2020, and the consistent finding across multiple independent research groups is that the condition involves biology that was partly established before the infection occurred. The inflammatory architecture of Long COVID, the cytokine elevation, the immune exhaustion, the failure of resolution, reflects the interaction between a novel virus and a set of pre-existing genomic configurations that determine how the immune system responds, amplifies, and resolves a threat.

The same virus infects two genetically distinct people and produces two different post-infection trajectories. The difference in outcome does not originate in the virus. It originates in the genomic instructions that govern how each person's immune system handles the virus.

Understanding the genomic layer of Long COVID is the first step in understanding why the condition persists, who carries the greatest biological vulnerability, and where the biology of recovery and non-recovery diverges at the molecular level. This platform covers that biology in depth. Every piece of content here is grounded in peer-reviewed research, and none of it constitutes medical advice. Clinical interpretation is handled separately through qualified medical providers.

Disclaimer: The content on this platform is strictly educational and informational. Nothing here constitutes a medical diagnosis, clinical assessment, or treatment recommendation. All clinical decisions are handled separately through qualified medical providers.